Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial

Table 1 Summary of ceftolozane and tazobactam steady-state plasma exposures in patients with HABP/VABP

Exposure measure	Statistic	Ceftolozane				Tazobactam
Exposure measure	Statistic	CrCl ≥ 80 to < 150 mL/min	CrCL ≥ 150 to < 180 mL/min	CrCL ≥ 180 to < 210 mL/min	CrCL ≥ 210 mL/min	CrCl ≥ 80 to < 150 mL/min	CrCL ≥ 150 to < 180 mL/min	CrCL ≥ 180 to < 210 mL/min	CrCL ≥ 210 mL/min
AUC_0–8 (μg × h/mL)	n	138	24	16	20	138	24	16	20
AUC_0–8 (μg × h/mL)	Geometric mean (geometric %CV)	371 (55.3)	276 (52.6)	248 (59.7)	201 (67.2)	61.9 (80.1)	42.1 (56.2)	42.0 (90.7)	34.8 (85.6)
C_max (μg/mL)	n	138	24	16	20	138	24	16	20
C_max (μg/mL)	Geometric mean (geometric %CV)	103 (42.6)	88.6 (40.2)	78.0 (52.7)	65.3 (63.0)	25.8 (45.0)	21.0 (34.3)	19.6 (43.6)	18.6 (48.8)

Among all participants from the intention-to-treat population who had pharmacokinetic data collected
AUC_0–8, area under the concentration–time curve from time 0 to 8 h after start of infusion; C_max, maximum drug concentration; CrCl, creatinine clearance; CV, coefficient of variation; HABP/VABP, hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia

ISSN: 1364-8535